CTBP1 and cancer: Although the first evidence for a role of β-ARs in cancer progression was provided more than 20 years ago [7], the serendipitous observation of the efficacy of propranolol in treating haemangiomas has renewed interest in exploring the anti-angiogenic and anti-cancer properties of β-AR antagonists (also called β-blockers).